DZD9008

DRUG4 trials

Sponsors

Dizal Pharmaceuticals, Peking Union Medical College Hospital

Conditions

Healthy VolunteersHepatic ImpairmentNon Small Cell Lung CancerNon-Hodgkin's B-cell Lymphoma

Phase 1

Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)

WithdrawnNCT04148742

Dizal PharmaceuticalsNon-Hodgkin's B-cell Lymphoma

Start: 2021-08-31End: 2023-07-31Updated: 2025-02-25

Assessing the Safety, Tolerability and Pharmacokinetics(PK) of DZD9008 and the Effect of Low-fat Meal on PK of DZD9008 in Healthy Adult Participants

CompletedNCT04909242

Dizal PharmaceuticalsHealthy Volunteers

Start: 2021-04-21End: 2022-02-07Updated: 2022-06-02

DZD9008 PK Study in Hepatic Impairment Subjects

CompletedNCT06084104

Dizal PharmaceuticalsHepatic Impairment

Start: 2023-10-17End: 2024-10-23Updated: 2024-12-18

Unknown Phase

Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)

RecruitingNCT05559645

Peking Union Medical College HospitalNon Small Cell Lung Cancer

Start: 2021-11-18End: 2027-06-30Target: 180Updated: 2026-09-02

Related Papers

Efficacy and safety of sunvozertinib monotherapy as first-line treatment in NSCLC patients with EGFR exon 20 insertion mutations: A phase 2, single-center trial.

2025-07-051 citations

Efficacy and safety of sunvozertinib in treatment naïve NSCLC patients with EGFR exon20 insertion mutations.

Journal of Clinical Oncology2023-06-0114 citations

Anti-tumor activity of sunvozertinib in NSCLC with EGFR sensitizing mutations after failure of EGFR TKI treatment.

Journal of Clinical Oncology2023-06-015 citations